Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 59 results.
User Information
Export Records
  1. 1.   Adoptive transfer of membrane-restricted IL-12-TCR T cells promotes antigen spreading and elimination of antigen-negative tumor variants
  2. Zhang, Ling; Norberg, Scott M; Karimipour, Farrah; Davies, John S; Kuznetsov, Alex; Lassoued, Wiem; Burnett, Daniel; Homan,Philip; Cam, Margaret; Sinkoe, Andrew; Xue, Ping; Gulley, James L; Hinrichs, Christian S
  3. Journal for Immunotherapy of Cancer. 2024, Nov 18; 12(11):
  1. 2.   Divergent HLA variations and heterogeneous expression but recurrent HLA loss-of- heterozygosity and common HLA-B and TAP transcriptional silencing across advanced pediatric solid cancers
  2. Lim, Wan Ching; Marques Da Costa, Maria Eugenia; Godefroy, Karine; Jacquet, Eric; Gragert, Loren; Rondof, Windy; Marchais, Antonin; Nhiri, Naima; Dalfovo, Davide; Viard,Mathias; Labaied, Nizar; Khan, Asif M; Dessen, Philippe; Romanel, Alessandro; Pasqualini, Claudia; Schleiermacher, Gudrun; Carrington,Mary; Zitvogel, Laurence; Scoazec, Jean-Yves; Geoerger, Birgit; Salmon, Jerome
  3. Frontiers in Immunology. 2024, Jan 22; 14: 1265469.
  1. 3.   NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer
  2. Salomé, Bérengère; Sfakianos, John P; Ranti, Daniel; Daza, Jorge; Bieber, Christine; Charap, Andrew; Hammer, Christian; Banchereau, Romain; Farkas, Adam M; Ruan, Dan Fu; Izadmehr, Sudeh; Geanon, Daniel; Kelly, Geoffrey; de Real, Ronaldo M; Lee, Brian; Beaumont, Kristin G; Shroff, Sanjana; Wang, Yuanshuo A; Wang, Ying-Chih; Thin, Tin Htwe; Garcia-Barros, Monica; Hegewisch-Solloa, Everardo; Mace, Emily M; Wang, Li; O'Donnell, Timothy; Chowell, Diego; Fernandez-Rodriguez, Ruben; Skobe, Mihaela; Taylor, Nicole; Kim-Schulze, Seunghee; Sebra, Robert P; Palmer, Doug; Clancy-Thompson, Eleanor; Hammond, Scott; Kamphorst, Alice O; Malmberg, Karl-Johan; Marcenaro, Emanuela; Romero, Pedro; Brody, Rachel; Viard,Mathias; Yuki,Yuko; Martin,Pat; Carrington,Mary; Mehrazin, Reza; Wiklund, Peter; Mellman, Ira; Mariathasan, Sanjeev; Zhu, Jun; Galsky, Matthew D; Bhardwaj, Nina; Horowitz, Amir
  3. Cancer Cell. 2022, Sep 12; 40(9): 1027-1043.e9.
  1. 4.   A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer
  2. Manzo, Julia; Puhalla, Shannon; Pahuja, Shalu; Ding, Fei; Lin, Yan; Appleman, Leonard; Tawbi, Hussein; Stoller, Ronald; Lee, James J; Diergaarde, Brenda; Kiesel, Brian F; Yu, Jing; Tan, Antoinette R; Belani, Chandra P; Chew, Helen; Garcia, Agustin A; Morgan, Robert J; Wahner Hendrickson, Andrea E; Visscher, Daniel W; Hurley, Rachel M; Kaufmann, Scott H; Swisher, Elizabeth M; Oesterreich, Steffi; Katz, Tiffany; Ji,Jay; Zhang, Yiping; Parchment, Ralph E; Chen, Alice; Duan, Wenrui; Giranda, Vincent; Shepherd, Stacie P; Ivy, S Percy; Chu, Edward; Beumer, Jan H
  3. Cancer Chemotherapy and Pharmacology. 2022, Apr 18; 89(5): 721-735.
  1. 5.   Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial
  2. Kalinsky, Kevin; Hong, Fangxin; McCourt, Carolyn K.; Sachdev, Jasgit C.; Mitchell, Edith P.; Zwiebel, James A.; Doyle, L. Austin; McShane, Lisa M.; Li, Shuli; Gray, Robert J.; Rubinstein, Larry V.; Patton, David; Williams,Mickey; Hamilton, Stanley R.; Conley, Barbara A.; O'Dwyer, Peter J.; Harris, Lyndsay N.; Arteaga, Carlos L.; Chen, Alice P.; Flaherty, Keith T.
  3. JAMA oncology. 2021, Feb 1; 7(2): 271-278.
  1. 6.   Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H
  2. Salama, April K S; Li, Shuli; Macrae, Erin R; Park, Jong-In; Mitchell, Edith P; Zwiebel, James A; Chen, Helen X; Gray, Robert J; McShane, Lisa M; Rubinstein, Larry V; Patton, David; Williams,Mickey; Hamilton, Stanley R; Armstrong, Deborah K; Conley, Barbara A; Arteaga, Carlos L; Harris, Lyndsay N; O'Dwyer, Peter J; Chen, Alice P; Flaherty, Keith T
  3. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020, NOV 20; 38(33): JCO2000762.
  1. 7.   Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W
  2. Chae, Young K; Hong, Fangxin; Vaklavas, Christos; Cheng, Heather H; Hammerman, Peter; Mitchell, Edith P; Zwiebel, James A; Ivy, S Percy; Gray, Robert J; Li, Shuli; McShane, Lisa M; Rubinstein, Larry V; Patton, David; Williams,Mickey; Hamilton, Stanley R; Mansfield, Aaron; Conley, Barbara A; Arteaga, Carlos L; Harris, Lyndsay N; O'Dwyer, Peter J; Chen, Alice P; Flaherty, Keith T
  3. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020, JUL 20; 38(21): 2407-+.
  1. 8.   PI3K inhibitors: review and new strategies
  2. Zhang,Mingzhen; Jang,Hyunbum; Nussinov,Ruth
  3. CHEMICAL SCIENCE. 2020, JUN 21; 11(23): 5855-5865.
  1. 9.   Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study
  2. Azad, Nilofer S; Gray, Robert J; Overman, Michael J; Schoenfeld, Jonathan D; Mitchell, Edith P; Zwiebel, James A; Sharon, Elad; Streicher, Howard; Li, Shuli; McShane, Lisa M; Rubinstein, Larry; Patton, David R; Williams,Mickey; Coffey,Brent; Hamilton, Stanley R; Bahary, Nathan; Suga, J Marie; Hatoum, Hassan; Abrams, Jeffrey S; Conley, Barbara A; Arteaga, Carlos L; Harris, Lyndsay; O'Dwyer, Peter J; Chen, Alice P; Flaherty, Keith T
  3. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020, JAN 20; 38(3): 214-+.
  1. 10.   Structure-activity relationship studies and in vitro and in vivo anticancer activity of novel 3-aroyl-1,4-diarylpyrroles against solid tumors and hematological malignancies
  2. Puxeddu, Michela; Shen, Hongliang; Bai,Ruoli; Coluccia, Antonio; Nalli, Marianna; Mazzoccoli, Carmela; Da Pozzo, Eleonora; Cavallini, Chiara; Martini, Claudia; Orlando, Viviana; Biagioni, Stefano; Mazzoni, Cristina; Coluccia, Addolorata Maria Luce; Hamel,Ernest; Liu, Te; Silvestri, Romano; La Regina, Giuseppe
  3. European journal of medicinal chemistry. 2020, Jan 1; 185: 111828.
  1. 11.   Blood Interactions, Pharmacokinetics, and Depth-Dependent Ablation of Rat Mammary Tumors with Photoactivatable, Liposomal Doxorubicin
  2. Carter, Kevin A.; Luo, Dandan; Geng, Jumin; Stern, Steve; Lovell, Jonathan F.
  3. Molecular cancer therapeutics. 2019, Mar; 18(3): 592-601.
  1. 12.   Preclinical therapeutic response of residual metastatic disease is distinct from its primary tumor of origin
  2. Day, C. P.; Carter, J.; Bonomi, C.; Hollingshead, M.; Merlino, G.
  3. International Journal of Cancer. 2012, Jan; 130(1): 190-199.
  1. 13.   A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer
  2. Kelly, R. J.; Draper, D.; Chen, C. C.; Robey, R. W.; Figg, W. D.; Piekarz, R. L.; Chen, X. H.; Gardner, E. R.; Balis, F. M.; Venkatesan, A. M.; Steinberg, S. M.; Fojo, T.; Bates, S. E.
  3. Clinical Cancer Research. 2011, Feb; 17(3): 569-580.
  1. 14.   Identification of Four Potential Epigenetic Modulators from the NCI Structural Diversity Library Using a Cell-Based Assay
  2. Best, A. M.; Chang, J. J.; Dull, A. B.; Beutler, J. A.; Martinez, E. D.
  3. Journal of Biomedicine and Biotechnology. 2011 11.
  1. 15.   The Development and Characterization of a Human Mesothelioma In Vitro 3D Model to Investigate Immunotoxin Therapy
  2. Xiang, X. R.; Phung, Y.; Feng, M. Q.; Nagashima, K.; Zhang, J. L.; Broaddus, V. C.; Hassan, R.; FitzGerald, D.; Ho, M.
  3. Plos One. 2011, Jan; 6(1): 10.
  1. 16.   Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma
  2. Bates, S. E.; Zhan, Z. R.; Steadman, K.; Obrzut, T.; Luchenko, V.; Frye, R.; Robey, R. W.; Turner, M.; Gardner, E. R.; Figg, W. D.; Steinberg, S. M.; Ling, A.; Fojo, T.; To, K. W.; Piekarz, R. L.
  3. British Journal of Haematology. 2010, Jan; 148(2): 256-267.
  1. 17.   Recent Development of Cyclic Amide (Pyridone/Lactam) Moiety Containing Heterocycles as Protein Kinase Inhibitors
  2. Wei, L. Y.; Malhotra, S. V.
  3. Current Medicinal Chemistry. 2010, Jan; 17(3): 234-253.
  1. 18.   Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies
  2. Kummar, S.; Gutierrez, M. E.; Gardner, E. R.; Chen, X. H.; Figg, W. D.; Zajac-Kaye, M.; Chen, M.; Steinberg, S. M.; Muir, C. A.; Yancey, M. A.; Horneffer, Y. R.; Juwara, L.; Melillo, G.; Ivy, S. P.; Merino, M.; Neckers, L.; Steeg, P. S.; Conley, B. A.; Giaccone, G.; Doroshow, J. H.; Murgo, A. J.
  3. European Journal of Cancer. 2010, Jan; 46(2): 340-347.
  1. 19.   Approaching Solid Tumor Heterogeneity on a Cellular Basis by Tissue Proteomics Using Laser Capture Microdissection and Biological Mass Spectrometry
  2. Johann, D. J.; Rodriguez-Canales, J.; Mukherjee, S.; Prieto, D. A.; Hanson, J. C.; Emmert-Buck, M.; Blonder, J.
  3. Journal of Proteome Research. 2009 8(5): 2310-2318.
  1. 20.   Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts
  2. Monks, A.; Hose, C. D.; Pezzoli, P.; Kondapaka, S.; Vansant, G.; Petersen, K. D.; Sehested, M.; Monforte, J.; Shoemaker, R. H.
  3. Anti-Cancer Drugs. 2009 20(8): 682-692.
  1. 21.   Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition
  2. Rapisarda, A.; Hollingshead, M.; Uranchimeg, B.; Bonomi, C. A.; Borgel, S. D.; Carter, J. P.; Gehrs, B.; Raffeld, M.; Kinders, R. J.; Parchment, R.; Anver, M. R.; Shoemaker, R. H.; Melillo, G.
  3. Molecular Cancer Therapeutics. 2009 8(7): 1867-1877.
  1. 22.   Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody
  2. Cao, L.; Yu, Y. K.; Darko, I.; Currier, D.; Mayeenuddin, L. H.; Wan, X. L.; Khanna, C.; Helman, L. J.
  3. Cancer Research. 2008 68(19): 8039-8048.
  1. 23.   Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198
  2. LaVallee, T. M.; Burke, P. A.; Swartz, G. M.; Hamel, E.; Agoston, G. E.; Shah, J.; Suwandi, L.; Hanson, A. D.; Fogler, W. E.; Sidor, C. F.; Treston, A. M.
  3. Molecular Cancer Therapeutics. 2008 7(6): 1472-1482.
  1. 24.   Substitution of Aminomethyl at the Meta-Position Enhances the Inactivation of O-6-Alkylguanine-DNA Alkyltransferase by O-6-Benzylguanine
  2. Pauly, G. T.; Loktionova, N. A.; Fang, Q. M.; Vankayala, S. L.; Guida, W. C.; Pegg, A. E.
  3. Journal of Medicinal Chemistry. 2008 51(22): 7144-7153.
  1. 25.   HER2-Specific Affibody-Conjugated Thermosensitive Liposomes (Affisomes) for Improved Delivery of Anticancer Agents
  2. Puri, A.; Kramer-Marek, G.; Campbell-Massa, R.; Yavlovich, A.; Tele, S. C.; Lee, S. B.; Clogston, J. D.; Patri, A. K.; Blumenthal, R.; Capala, J.
  3. Journal of Liposome Research. 2008 18(4): 293-307.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel